ASX:MSBBiotechs
Mesoblast (ASX:MSB) Valuation Check As Ryoncil Access And Early Commercial Outcomes Progress
Mesoblast (ASX:MSB) is back in focus after reporting early commercial experience with Ryoncil in children with steroid refractory acute graft versus host disease, along with broader US access and reimbursement progress.
See our latest analysis for Mesoblast.
That clinical and reimbursement progress comes after a mixed year for the stock, with a 7.17% 90 day share price return, a 7.24% 30 day share price decline, and a very large 3 year total shareholder return of 198.64%. This suggests longer...